AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33156761 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Radiography (CXR)
Number of subjects: 72985
Study 35848978 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure with magnetic plates (study group)
Number of subjects: 195
Study 35848978 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure without magnetic plates (placebo group)
Number of subjects: 195
Study 35848978 — intervention group
Group type: COMPARATOR
Intervention: Routine post cesarean pain management (control group)
Number of subjects: 195
Study 34011035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailing Capsule (BC) combined with α-ketoacid tablets (KA)
Number of subjects: 0
Study 34011035 — intervention group
Group type: COMPARATOR
Intervention: BC-simulation combined with α-ketoacid tablets (KA)
Number of subjects: 0
Study 32128848 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (600 mg)
Number of subjects: 26
Study 36164037 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP + tafasitamab (12 mg/kg IV, D1, 8, 15)
Number of subjects: 130
Study 36164037 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP + tafasitamab + lenalidomide (25 mg orally, D1-10)
Number of subjects: 130
Study 33713329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini craniotomy
Number of subjects: 0
Study 33713329 — intervention group
Group type: COMPARATOR
Intervention: Full-fledged craniotomy and endoscopy-guided surgery
Number of subjects: 0
Study 32989825 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (50 mg/kg−1)
Number of subjects: 117
Study 32989825 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic tranexamic acid (20 mg/kg−1 through cardiopulmonary bypass and another 20 mg/kg−1 after separation)
Number of subjects: 117
Study 32989825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antifibrinolytics)
Number of subjects: 117
Study 35656757 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Loteprednol etabonate (LE)
Number of subjects: 100
Study 35656757 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Fluorometholone (FML)
Number of subjects: 100
Study 34399759 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent inject® + concurrent cataract surgery
Number of subjects: 0
Study 34399759 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone
Number of subjects: 0
Study 32464421 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaves extract (MOLE) at a dose of 40 mg/kg orally daily
Number of subjects: 24
Study 32464421 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E and selenium at a dose of 3 ml (4.5 mg sodium selenite and 204 mg vitamin E)/head i.m twice a week for 64 days
Number of subjects: 24
Study 32464421 — intervention group
Group type: COMPARATOR
Intervention: Distilled water orally
Number of subjects: 24
Study 36099091 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Number of subjects: 20
Study 36099091 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 20
Study 616835912 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strength training followed by task-oriented strength training (EST-TOST)
Number of subjects: 11
Study 616835912 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented strength training followed by eccentric strength training (TOST-EST)
Number of subjects: 11
Study 616835912 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strength training and task-oriented strength training
Number of subjects: 11
Study 35112815 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume cluster sets (CLUS)
Number of subjects: 20
Study 35112815 — intervention group
Group type: COMPARATOR
Intervention: Lower-volume traditional sets (TRAD)
Number of subjects: 20
Study 32472001 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib tablets (300 mg twice daily)
Number of subjects: 87
Study 32472001 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy treatment of physician's choice (TPC)
Number of subjects: 87
Study 36078247 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 204
Study 33532956 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Shared Medical Appointments (SMAs) totaling 8–9 hours
Number of subjects: 1537
Study 33532956 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1537
Study 35598114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine alone (600 mg base)
Number of subjects: 119
Study 35598114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine with azithromycin (500 mg)
Number of subjects: 119
Study 35598114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine with azithromycin (1,000 mg)
Number of subjects: 119
Study 35598114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine with azithromycin (1,500 mg)
Number of subjects: 119
Study 35598114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 33225343 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (n = 123)
Number of subjects: 256
Study 33225343 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 133)
Number of subjects: 256
Study 32614987 — intervention group
Group type: EXPERIMENTAL
Intervention: IncoA intradermal injection (100 unit or 1 vial in 6 cc of NSS)
Number of subjects: 22
Study 32614987 — intervention group
Group type: EXPERIMENTAL
Intervention: IncoA intradermal injection
Number of subjects: 22
Study 32614987 — intervention group
Group type: COMPARATOR
Intervention: NSS
Number of subjects: 22
Study 36036107 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumbtack needling therapy
Number of subjects: 135
Study 36036107 — intervention group
Group type: COMPARATOR
Intervention: Sham-thumbtack needling therapy
Number of subjects: 135
Study 36036107 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 135
Study 36036107 — intervention group
Group type: COMPARATOR
Intervention: Medication group (PCA)
Number of subjects: 135
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Food habits (various dietary components assessed via structured questionnaire)
Number of subjects: 924
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Food habits (specific habits assessed)
Number of subjects: 924
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating dinner often
Number of subjects: 924
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Having breakfast before school often
Number of subjects: 924
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating cake or dessert at meal often
Number of subjects: 924
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking eight glasses of water often
Number of subjects: 924
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating food from school canteen often
Number of subjects: 924
Study 33612607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bringing own snack from home often
Number of subjects: 924
Study 34227956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-supported care
Number of subjects: 108
Study 34227956 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 32423457 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal test and treat (UTT) program
Number of subjects: 500
Study 32423457 — intervention group
Group type: COMPARATOR
Intervention: Differed treatment program
Number of subjects: 500
Study 36459357 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic vertical clip gastroplasty (LVCG)
Number of subjects: 50
Study 34688102 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SAVE (30-min, web-based, single-session intervention)
Number of subjects: 565
Study 34688102 — intervention group
Group type: COMPARATOR
Intervention: Active, attention-matched control program
Number of subjects: 565
Study 35811299 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) education
Number of subjects: 30
Study 35811299 — intervention group
Group type: COMPARATOR
Intervention: Conventional leaflets provided by asthma specialists (control group)
Number of subjects: 30
Study 35811299 — intervention group
Group type: COMPARATOR
Intervention: Both groups (VR and control)
Number of subjects: 30
Study 33148686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose gel (buccal 40% dextrose gel)
Number of subjects: 360
Study 33148686 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dextrose
Number of subjects: 360
Study 33148686 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who developed neonatal hypoglycaemia
Number of subjects: 360
Study 32040014 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV (tetravalent dengue vaccine)
Number of subjects: 9740
Study 32040014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9740
Study 36070590 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with LED irradiation
Number of subjects: 14
Study 36070590 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (LED-off)
Number of subjects: 14
Study 33983111 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized interface/mask fitting session supervised by a certified sleep technician
Number of subjects: 156
Study 33983111 — intervention group
Group type: COMPARATOR
Intervention: Usual care (obtaining an interface through durable medical equipment suppliers)
Number of subjects: 156
Study 32559034 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate DBBM
Number of subjects: 17
Study 32559034 — intervention group
Group type: COMPARATOR
Intervention: Block DBBM
Number of subjects: 17
Study 35284687 — intervention group
Group type: EXPERIMENTAL
Intervention: HAZMAT workshop
Number of subjects: 100
Study 35284687 — intervention group
Group type: COMPARATOR
Intervention: waitlist
Number of subjects: 100
Study 33691183 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 948
Study 33691183 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 948
Study 36357085 — intervention group
Group type: EXPERIMENTAL
Intervention: TEER plus guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 36357085 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study 35716139 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling with HPV mRNA testing
Number of subjects: 5350
Study 35716139 — intervention group
Group type: COMPARATOR
Intervention: Routine screening
Number of subjects: 5350
Study 33390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (fluticasone)
Number of subjects: 9
Study 33390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 9
Study 33390654 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study 36303867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram including variables such as radiotherapy, primary site surgery, Ann Arbor Stage, chemotherapy, histological subtype, and age at diagnosis.
Number of subjects: 1152
Study 36303867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 5-, 10-, and 15-year BC-PTML cancer-specific survival (CSS).
Number of subjects: 1152
Study 36303867 — intervention group
Group type: COMPARATOR
Intervention: Traditional Ann Arbor staging system.
Number of subjects: 1152
Study 34737091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (alpha-2 adrenergic agonist)
Number of subjects: 0
Study 34737091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33620562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 108
Study 33620562 — intervention group
Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 108
Study 33620562 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS score for sore throat on POD 1
Number of subjects: 108
Study 33620562 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS score for sore throat on POD 2
Number of subjects: 108
Study 33216357 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp reminder (WR)
Number of subjects: 500
Study 33216357 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp reminder (WR) after crossover
Number of subjects: 500
Study 36216309 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (109CFU of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei and Bifidobacterium lactis)
Number of subjects: 46
Study 36216309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 36216309 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 46
Study 33533820 — intervention group
Group type: EXPERIMENTAL
Intervention: Early therapy (rehabilitative protocol started immediately after the initial evaluation)
Number of subjects: 29
Study 33533820 — intervention group
Group type: COMPARATOR
Intervention: Late therapy (rehabilitative protocol started 10 weeks later)
Number of subjects: 29
Study 35886189 — intervention group
Group type: EXPERIMENTAL
Intervention: PPFF intervention (12 hr, 8 session)
Number of subjects: 68
Study 35886189 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (50 hr, 25 session)
Number of subjects: 68
Study 33318005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam
Number of subjects: 351
Study 33318005 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 351
Study 32067249 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0284 (4-238 mg single dose or 12-100 mg multiple doses)
Number of subjects: 83
Study 32067249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 33878856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg every 2 weeks) with concomitant topical corticosteroids
Number of subjects: 299
Study 32920792 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM risk score
Number of subjects: 100
Study 35918313 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (SUV); 10 mg
Number of subjects: 21
Study 35918313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 32888746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor exercise program (thrice a week for 12 weeks)
Number of subjects: 33
Study 32888746 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 33
Study 32962743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 32962743 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 35367136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed allergenic food powder (MP) containing egg, milk, wheat, soybean, buckwheat, and peanuts, administered in increasing amounts until week 12
Number of subjects: 163
Study 35367136 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder (PP)
Number of subjects: 163
Study 33766017 — intervention group
Group type: EXPERIMENTAL
Intervention: MyFood decision support system
Number of subjects: 100
Study 36290823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling provided by registered dietitians at least every two weeks during antineoplastic treatment
Number of subjects: 61
Study 36290823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Number of subjects: 61
Study 36290823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 61
Study 34167705 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation body massager type A (two small pads)
Number of subjects: 20
Study 34167705 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation body massager type B (one large pad)
Number of subjects: 20
Study 34953531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral octreotide (40 mg a day, optional titration to 60 or 80 mg a day)
Number of subjects: 92
Study 34953531 — intervention group
Group type: COMPARATOR
Intervention: Injectable somatostatin receptor ligands (iSRLs) at the same dose and interval as before enrolment
Number of subjects: 92
Study 34953531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral octreotide
Number of subjects: 92
Study 34953531 — intervention group
Group type: COMPARATOR
Intervention: Injectable somatostatin receptor ligands (iSRLs)
Number of subjects: 92
Study 32171169 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral strength training (CST)
Number of subjects: 28
Study 32171169 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct strength training (DST)
Number of subjects: 28
Study 32931725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemicals
Number of subjects: 791
Study 32931725 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol
Number of subjects: 791
Study 32931725 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived harm of secondhand e‐cigarette exposure
Number of subjects: 791
Study 32071129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal aspiration
Number of subjects: 16
Study 32071129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal suctioning
Number of subjects: 16
Study 32071129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both suctioning techniques
Number of subjects: 16
Study 34382434 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 34382434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33038338 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 30
Study 36226327 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational trial
Number of subjects: 17
Study 36226327 — intervention group
Group type: COMPARATOR
Intervention: Randomized trial
Number of subjects: 17
Study 33612449 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytics and plasma products (including intravenous immunoglobulin)
Number of subjects: 51
Study 33612449 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA matched products (Grade A or B1U)
Number of subjects: 51
Study 33612449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding-related mortality
Number of subjects: 51
Study 33612449 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant bleeding (by ISTH criteria)
Number of subjects: 51
Study 33612449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhagic shock
Number of subjects: 51
Study 32822076 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger flexors (FFs)
Number of subjects: 32
Study 32822076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle plantar flexors (PFs)
Number of subjects: 32
Study 35093278 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip treatment
Number of subjects: 614
Study 35093278 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study 33536271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alteplase
Number of subjects: 490
Study 33536271 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose alteplase
Number of subjects: 490
Study 33536271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vs Standard-dose alteplase
Number of subjects: 490
Study 35398218 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06826647 200 mg
Number of subjects: 178
Study 35398218 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06826647 400 mg
Number of subjects: 178
Study 35398218 — intervention group
Group type: COMPARATOR
Intervention: PF-06826647
Number of subjects: 178
Study 32772474 — intervention group
Group type: EXPERIMENTAL
Intervention: MarginProbe device
Number of subjects: 46
Study 32772474 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoperative assessments (Control)
Number of subjects: 46
Study 34261093 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting therapy (cabotegravir with rilpivirine, dosed every 4 weeks)
Number of subjects: 52
Study 34261093 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch arm (transition from current antiretroviral therapy to long-acting therapy)
Number of subjects: 52
Study 34261093 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting therapy (cabotegravir with rilpivirine)
Number of subjects: 52
Study 33078655 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families America (HFA) program
Number of subjects: 139
Study 33078655 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal care and coordination (PNCC) program
Number of subjects: 139
Study 33078655 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (quasi-experimental group)
Number of subjects: 139
Study 32925908 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study 32925908 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue characteristics (adipose MT gene expression, body fat percent, adipose cell types)
Number of subjects: 0
Study 35183744 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pHisoHex (hexachlorophene [1% triclosan; sodium benzoate, 5 mg/mL; and benzyl alcohol, 5 mg/mL])
Number of subjects: 101
Study 35183744 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Benzoyl Peroxide (BPO)
Number of subjects: 101
Study 35183744 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Benzoyl Peroxide with 1% Clindamycin (BPO-C)
Number of subjects: 101
Study 33556935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weight-loss lifestyle intervention with an energy-reduced Mediterranean diet (erMedDiet), physical activity promotion, and behavioral support
Number of subjects: 6719
Study 33556935 — intervention group
Group type: COMPARATOR
Intervention: Usual-care advice to adhere to an energy-unrestricted Mediterranean diet
Number of subjects: 6719
Study 33556935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weight-loss lifestyle intervention with an energy-reduced Mediterranean diet (erMedDiet)
Number of subjects: 6719
Study 32838763 — intervention group
Group type: EXPERIMENTAL
Intervention: col-ACP intervention (6 sessions)
Number of subjects: 270
Study 32838763 — intervention group
Group type: COMPARATOR
Intervention: supportive intervention (active control group)
Number of subjects: 270
Study 32838763 — intervention group
Group type: COMPARATOR
Intervention: standard medical care (TAU)
Number of subjects: 270